[
    [
        {
            "time": "2018-03-15",
            "original_text": "Why Celgene's Blockbuster Cancer Drug Looks Safe â€” For Now",
            "features": {
                "keywords": [
                    "Celgene",
                    "Blockbuster",
                    "Cancer Drug",
                    "Safe"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Dow Analyst Moves: JNJ",
            "features": {
                "keywords": [
                    "Dow",
                    "Analyst",
                    "JNJ"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-05-20",
            "original_text": "Novartis's Alcon sees myopia epidemic driving sales growth",
            "features": {
                "keywords": [
                    "Novartis",
                    "Alcon",
                    "myopia",
                    "sales growth"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "ophthalmology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-06-12",
            "original_text": "Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan",
            "features": {
                "keywords": [
                    "Glaxo",
                    "GSK",
                    "J&J",
                    "HIV Drug",
                    "Juluca",
                    "Approval",
                    "Japan"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-05",
            "original_text": "3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far",
            "features": {
                "keywords": [
                    "Glaxo",
                    "GSK",
                    "Stock",
                    "Up",
                    "Year"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-08-18",
            "original_text": "Noteworthy ETF Inflows: IWD, JPM, XOM, JNJ",
            "features": {
                "keywords": [
                    "ETF",
                    "Inflows",
                    "IWD",
                    "JPM",
                    "XOM",
                    "JNJ"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "energy",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-09-25",
            "original_text": "The Zacks Analyst Blog Highlights: Boeing, Microsoft, Johnson & Johnson, Chevron and Pfizer",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst",
                    "Blog",
                    "Boeing",
                    "Microsoft",
                    "Johnson & Johnson",
                    "Chevron",
                    "Pfizer"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "aerospace",
                    "technology",
                    "healthcare",
                    "energy"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-10",
            "original_text": "AMAG's Label Expansion of Lead Products Raises Share Price",
            "features": {
                "keywords": [
                    "AMAG",
                    "Label Expansion",
                    "Lead Products",
                    "Share Price"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]